Portai, a Tel Aviv, Israel-based proteomics and AI-powered drug discovery startup, raised additional $12M in Seed funding.
The round, which brought the total amount to $20M, was led by Grove Ventures and Pitango HealthTech and was joined by Maj Invest Equity Fund.
The company intends to use the funds to build its oncology drug discovery pipeline, expand data acquisition, as well as increase its discovery activities via pharma partnerships.
Founded by Eran Seger and Kirill Pevzner, Protai empowers drug discovery and development with proteomic response biomarkers and artificial intelligence to unlock new layers of biological insights and to combat complex diseases. Since its initial funding last year, the company has opened laboratories at its Israel R&D center for data acquisition, biological validation and drug discovery activities and recruited an experienced drug discovery team with experience in bringing drugs to the clinic. Additionally, Protai established collaborations with several leading hospitals, and now has access to over 100k well-defined banked samples for its comprehensive tumor mapping process, focused on gyno-oncology and lung cancer indications.
FinSMEs
15/03/2023